INTRODUCTION C
ERVICAL CANCER is the second most common cancer among women worldwide, with an estimated 493,000 new cases and 274,000 deaths in 2002 (Ferlay et al., 2002) , 83% of which occurred in developing countries. Whereas cytological screening has dramatically reduced the incidence of this disease in developed countries, in areas of the world where most women do not have access to regular gynecological care and screening cervical cancer accounts for 15% of female cancers (Ferlay et al., 2004) . It is firmly established that so-called high-risk human papillomavirus (HR-HPV) infections, particularly those related to HPV-16, cause cervical cancer (Zur Hausen, 2002 , 2006 International Agency for Research on Cancer, 2005) . The availability of preventive vaccines against HPVs (based on expression of , and -11 L1 structural protein assembled in virus-like particles, VLPs) represents a milestone in the prevention of this infection (Koutsky et al., 2002; Villa et al., 2005; Harper et al., 2006) , establishing the base for a significant reduction in the rate of cervical cancer in future. However, because of the long latency period between infection and cancer, the benefits of a prophylactic vaccination would be visible only after decades. Moreover, due to prohibitive costs, the use of these vaccines in developing countries is problematic. For these reasons research should be addressed both to therapeutic vaccines and low-cost production technologies.
The E7 oncoprotein of the HR-HPVs is able to immortalize primary human keratinocytes and, in cooperation with the viral E6 oncoprotein, is required for the induction and maintenance of HPV-associated malignancies (Munger et al., 2004) . Moreover, being expressed in all the cervical tumors and in precancerous lesions, the E7 protein represents a specific target for immunotherapy (Zur Hausen, 2002) . Several therapeutic HPVspecific E7-based vaccine formulations aimed at improving E7 "immune visibility" have been tested in animal models and encouraging results from phase 2 and 3 clinical trials have been reported (Frazer, 2004) .
Genetic immunization is a simple vaccination approach. DNA vaccines are relatively stable, inexpensive, easy to generate, and amenable to genetic modifications of the inserted sequences. They can induce adaptive immune responses, including activation of CD4 ϩ helper T cells and CD8 ϩ cytolytic T cells, making them attractive candidates for immunotherapy of cancer and chronic virus infections (Pardoll, 1998; Stevenson et al., 2004) .
Preclinical studies have shown that DNA vaccines encoding the E7 protein alone are less immunogenic and effective than DNA vaccines in which the E7 gene is fused to different carriers, such as calreticulin , Mycobacterium tuberculosis heat shock protein-70 (HSP70) (Chen et al., 2000) , lysosome-associated membrane protein-1 (Wu et al., 1995; Kang et al., 2006) , ubiquitin or invariant chain (De Marco et al., 2003) , or the translocation domain of Pseudomonas aeruginosa exotoxin A . All these strategies have been shown to be superior in antigen presentation and tumor eradication in mouse models. However, most of these approaches do not tackle some safety concerns in view of their clinical use, such as induction of autoimmune reactions (Millar et al., 2003) , oncogenicity potential in humans (Smahel et al., 2001) , or preexisting T cell immunity to the carrier protein (Savelyeva et al., 2001; Wolkers et al., 2002) .
Plant virus-derived sequences, in particular viral coat proteins (CPs), might offer new opportunities to activate immunity against HPV epitopes to attack cervical cancer. CPs have been largely used as carrier proteins for a range of B cell epitopes from animal pathogens (Scholthof et al., 1996; Cañizares et al., 2005) . Furthermore, by representing primary antigens in humans and having the ability to aggregate into structures able to increase the CD4 ϩ T cell immune response (Savelyeva et al., 2003) , CPs act like dominant pathogen-derived antigens able to enhance immunogenicity of silent or poor determinants (Gerloni et al., 2000) .
The aim of this study was to generate a safe and effective HPV-16 E7-based therapeutic DNA vaccine exploiting the potential of the coat protein (CP) of the plant virus potato virus X (PVX). PVX, the type member of the genus Potexvirus, is a monopartite RNA virus with a single coat protein of 237 amino acids that assembles into flexuous rod-shaped particles. An attenuated HPV-16 E7 gene (E7GGG), resulting in three amino acid substitutions in the retinoblastoma protein (pRb)-binding site, was fused to the 5Ј end of the PVX-CP gene, directly or via a four-amino acid linker. These DNA vaccines proved to be able to block the growth of tumors in C57BL/6 mice. The proposed DNA vaccine strategy shows promise for therapeutic control of HPV-16-induced tumors.
MATERIALS AND METHODS

Mice and cell lines
Six-week-old female C57BL/6 mice were purchased from Charles River (Como, Italy). Mice were maintained under specific pathogen-free conditions at the Experimental Animal Department of the Regina Elena Cancer Institute (Rome, Italy). Institutional animal use guidelines were followed for all experiments. E7-expressing TC-1 tumor cells were kindly provided by T.C. Wu (Johns Hopkins Medical Institutions, Baltimore, MD). HEK-293 cells, used for transfection experiments, were kindly provided by D. Neri (ETH-Hönggerberg, Zurich, Switzerland).
Mutagenesis of HPV-16 E7 gene, bacterial expression of E7GGG protein, and generation of recombinant mammalian expression vectors
To avoid safety concerns associated with the administration of an oncogene in humans, we used an attenuated HPV-16 E7 gene that had been demonstrated to be unable to transform cells. In particular, we mutagenized the DLYCYE motif (amino acids 21-26) into a GLYGYG sequence, obtaining the E7GGG gene (Smahel et al., 2001) . The HPV-16 E7 oncogene (CoreNucleotide accession number K02718), cloned into pQE30, was mutagenized with a QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). Primers E7GGGdir (5Ј-CAACAA-GAGACAACTGGTCTCTACGGTTATGGGCAATTAAAT-GACAGC-3Ј) and E7GGGrev (5Ј-GCTGTCATTTAATTGC-CCATAACCGTAGAGACCAGTTGTCTCTGGTTGC-3Ј) were used to introduce three point mutations into the pRb-binding site of the E7 gene, as indicated by the boldface oligonucleotides, obtaining the E7GGG gene. The introduced mutations result in the substitution of three amino acids in the E7 protein sequence: D21G (Asp 21 Ǟ Gly), C24G (Cys 24 Ǟ Gly), and E26G (Glu 26 Ǟ Gly). Sequence authenticity was confirmed by sequencing and the plasmid pQE30-E7GGG was used to transform competent Escherichia coli XL1-Blue cells.
The E7GGG gene was expressed in E. coli as a soluble His 6 -E7GGG protein and it was purified under nondenaturing conditions. After dialysis against phosphate-buffered saline (PBS)-0.1 mM ZnCl 2 , Coomassie blue-stained 12% sodium dodecyl sulfate (SDS)-polyacrylamide gels were used to determine the purity of samples. The amount of immunoreactive His 6 -E7GGG protein in the fractions was analyzed by immunoblotting assay with a mouse polyclonal antibody specific for HPV-16 E7 protein (diluted 1:1000, pAb ␣-E7) and, subsequently, with a sheep anti-mouse biotinylated secondary antibody (diluted 1:5000) and peroxidaselabeled streptavidin (diluted 1:2000) , all purchased by GE Healthcare Life Sciences (Uppsala, Sweden). Bound antibody was detected with the ECL Plus system (enhanced chemiluminescence; GE Healthcare Life Sciences).
For cloning in the pcDNA3.1(ϩ) mammalian expression vector (Invitrogen, Carlsbad, CA), the HPV-16 E7GGG sequence was amplified with the backward primer E7H3dir (5Ј-GGCCAAGCTTATCATGCATGGAGATACACCTACATT-3Ј; the added HindIII restriction site is underlined, the Kozak sequence for expression regulation in mammals is in boldface, and the E7 initiation translation codon is in italic) and the forward primer E7Notrev (5Ј-TTCTCGACTTGCGGCCGCTT-ATGGTTTCTGAGAACAGAT-3Ј; the added NotI restriction site is underlined and the E7 stop translation codon is in italic). After restriction digestion with HindIII and NotI, they were ligated into the HindIII/NotI sites of pcDNA3.1(ϩ), obtaining the pcDNA/E7GGG construct.
The coat protein of PVX (CP-PVXX3 sequence; CoreNucleotide accession number D00344) alone was also cloned in the same mammalian expression vector by using the primers CPH3dir (5Ј-GGCCAAGCTTATCATGTCAGCACCAGC-TAGCACA-3Ј; the added HindIII restriction site is underlined, the Kozak sequence for expression regulation in mammals is in boldface, and the CP initiation translation codon is in italic) and the forward primer CPNotrev flanked by the NotI restriction site (5Ј-TTCTCGACTTGCGGCCGCTTATGGTGGTG-GTAGAGTGAC-3Ј), obtaining the pcDNA/CP construct.
The E7GGG gene was fused in frame to the fourth codon of PVX-CP directly (E7GGG-CP) or via the four-amino acid linker Gly-Pro-Gly-Pro (E7GGG-L-CP). The genes were assembled by SOE-PCR (splicing by overlap extension-polymerase chain reaction). For the E7GGG-CP fusion, the E7GGG gene was amplified with the following primers: backward primer E7H3dir (see above) and forward primer CPE7rev incorporating the upstream part of the coat protein of PVX and the downstream nucleotides of the E7 gene (5Ј-CTGTGTTGT-GCTAGCTGGTGGTTTCTGAGAACAGATGGG-3Ј) or forward primer CPlinkE7rev incorporating the four-amino acid linker as well (5Ј-GCTAGCTGGAGGTCCGGGTCCTG-GTTTCTGAGAACAGATGGG-3Ј).
For amplification of the CP sequence, E7CPdir backward primer incorporating the downstream nucleotides of the E7 gene and the upstream part of the coat protein of PVX starting from the fourth codon (5Ј-ATCTGTTCTCAGAAACCACCAGC-TAGCACAACACAGCCC-3Ј), or E7linkCPdir backward primer incorporating the downstream nucleotides of the E7 gene, the four-amino acid linker, and the upstream part of the coat protein of PVX starting from the fourth codon (5Ј-CA-GAAACCAGGACCCGGACCTCCAGCTAGCACAA-CACAGCCC-3Ј) and the forward primer CPNotrev were used. Assembled genes were cloned into pBluescript-SK(ϩ), sequenced, and then subcloned into pcDNA3.1(ϩ) mammalian expression vector after digestion with HindIII and NotI restriction enzymes, obtaining the constructs pcDNA/E7GGG-CP and pcDNA/E7GGG-L-CP.
All the plasmids were propagated in E. coli XL1-Blue. Plasmids to be used in immunization experiments were extracted by alkaline lysis followed by CsCl gradient purification. Plasmids for cell transfection were prepared using the EndoFree plasmid maxi kit (Qiagen, Hilden, Germany) and dissolved in physiological saline solution to a final concentration of 1 mg/ml.
Mammalian cell transfection, RT-PCR analysis, and immunofluorescence staining
HEK-293 cells were grown on 6-well plates and transfected the next day with 1 g of each plasmid. Transfection was accomplished with a chemical reagent (Effectene transfection kit; Qiagen). Expression of E7GGG, E7GGG-CP, and E7GGG-L-CP genes was analyzed by reverse transcription (RT)-PCR and then by immunofluorescence. Forty-eight hours after transfection, total RNA was extracted with EXTRACT-ALL solution (Laboratoires Eurobio, Les Ulis, France) in accordance with the producer's instructions. One microgram of RNA was incubated with 1 unit of RNase-free DNase (Promega, Madison, WI) and then reverse transcription was performed with Promega reagents. PCR amplification was performed with the same primers used for cloning in pcDNA3.1(ϩ).
For immunofluorescence staining, HEK-293 cells were grown on multichamber glass slides and, 48 hr after transfection, they were washed twice with ice-cold PBS, fixed with 4% paraformaldehyde for 10 min, and permeabilized with 0.1% Triton X-100 in PBS. Samples were blocked with 5% nonfat dry milk in PBS. E7GGG and fusion antigens were stained with a 1:1000 dilution of a mouse pAb ␣-E7 followed by a 1:300 dilution of an anti-mouse biotinylated secondary antibody and a 1:50 dilution of fluorescein isothiocyanate (FITC)-conjugated streptavidin (Sigma-Aldrich, Steinheim, Germany). Nuclei were counterstained with 4Ј,6-diamidino-2-phenylindole (DAPI). Slides were examined with a fluorescence Axiolab microscope (Carl Zeiss, Oberkochen, Germany) interfaced with a CoolSNAP CCD camera (Photometrics/Roper Scientific, Tucson, AZ).
Detection of CP fusion proteins by immunoblotting after mammalian cell transfection
Expression of E7GGG, E7GGG-CP, and E7GGG-L-CP antigens was analyzed by immunoblotting after transient transfection of HEK-293 mammalian cells. Transfection was accomplished in the absence or presence of 25
; Calbiochem, Darmstadt, Germany) added to culture medium 24 hr posttransfection. Forty-eight hours after transfection, cells were washed twice with ice-cold PBS, scraped, resuspended in gel loading buffer 5ϫ diluted to a final concentration of 1ϫ with radioimmunoprecipitation assay (RIPA) lysis buffer, and boiled for 10 min. Proteins from about 1 ϫ 10 6 cells were analyzed by immunoblotting as previously described for His 6 -E7GGG from E. coli.
For immunoprecipitation, whole cell lysates (5 ϫ 10 6 cells) were combined with mouse pAb ␣-E7. Subsequently, immobilized protein L agarose (Pierce Biotechnology, Rockford, IL), an immunoglobulin light chain-binding protein, was added for 1 hr on a rocking platform. The resin was then washed six times with PBS and bound proteins were recovered by incubation in 1ϫ SDS loading buffer with 2-mercaptoethanol for 5 min at 100°C. Eluted proteins were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and then transferred onto polyvinylidene difluoride (PVDF) membrane. Protein detection was performed as described above.
Animal tumor challenge and DNA vaccination
Before vaccination with the various E7-containing DNA preparations, groups of six mice were challenged by subcutaneous injection via the flank with the minimal amount of cells able to induce tumors in 100% of the animals, namely 5 ϫ 10 4 E7-expressing TC-1 tumor cells per mouse. After immunization, tumor growth was monitored by visual inspection and palpation twice per week. A group of unvaccinated mice received the same amount of TC-1 cells as a natural tumor growth control.
Mice were vaccinated by intramuscular injection, into the tibialis muscle, of 100 g of plasmid (CsCl-purified pcDNA/E7GGG, pcDNA/E7GGG-CP, pcDNA/E7GGG-L-CP, or pcDNA/CP) per dose in 100 l of saline solution on days 3 and 10. The negative control was represented by a group of mice vaccinated with saline solution only. Experiments were performed three times.
Detection of anti-E7-specific antibodies
Evaluation of anti-E7-specific antibodies was performed in mice in the absence of tumor burden, 1 week after the last booster. Sera from each mice of the same group were analyzed for the presence of E7-specific antibodies by enzyme-linked immunosorbent assay (ELISA). Microtiter plates were coated overnight at 4°C with a 100-ng/well concentration of nonmutagenized recombinant His 6 -E7 or His 6 -E7GGG purified proteins from E. coli in PBS. Sera were diluted 1:100 in 2% MPBS (nonfat dry milk-PBS, w/v) and then added to the coated wells. Total IgGs were detected with horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG(HϩL) (MP Biomedicals Life Sciences, Solon, OH) diluted 1:10,000. A 1:1000 dilution of anti-E7 polyclonal antibody in 2% MPBS was used as a positive control. Enzymatic activity was measured by adding 2,2Ј-azino-bis(3-ethylbenzthiazoline sulfonate) substrate and absorbance was read at 405 nm on an ELISA microtiter plate reader.
Enzyme-linked immunospot assay for interferon-␥-secreting cells
HPV-16 E7-specific T cell precursors were detected by enzyme-linked immunospot assay (ELISPOT) (Miyahira et al., 1995) 1 week after the last booster. Nonchallenged animals were killed and spleens were removed. A single-cell suspension of splenocytes (1 ϫ 10 6 cells per well), harvested from each group of vaccinated mice, was added to microtiter wells coated with a rat anti-mouse IFN-␥ antibody (clone R4-6A2, 8 g/ml; BD Biosciences Pharmingen, San Diego, CA), along with interleukin-2 (50 units/ml; Sigma-Aldrich Italia, Milan, Italy). Samples were incubated at 37°C for 24-48 hr with a 10-g/ml concentration of a peptide corresponding to the E7-specific H-2D b cytotoxic T lymphocyte (CTL) MHC class I epitope (amino acids 49-57, RAHYNIVTF) for detecting E7-specific CD8 ϩ T cell precursors or a 1-g/ml concentration of E7 peptide containing an MHC class II epitope (amino acids 30-67) for detecting E7-specific CD4 ϩ T cell precursors . Plates were incubated with biotinylated anti-interferon (IFN)-␥ antibody (clone XMG1.2, 2 g/ml; BD Biosciences Pharmingen). Avidin-horseradish peroxidase (2.5 g/ml; Sigma-Aldrich Italia) was then added and cell spots were stained by adding filtered (pore size, 0.22 m) 3,3Ј-diaminobenzidine (DAB)-peroxidase substrate (SIGMAFAST; Sigma-Aldrich Italia) for 15 min. The spots were counted using a dissecting microscope.
RESULTS
E7GGG and PVX-CP fusion constructs are expressed in HEK-293 cells and are processed through the proteasome pathway
The E7GGG gene (Smahel et al., 2001 ) was first expressed in bacteria. The mutagenized His-tagged product showed faster electrophoretic migration on SDS-polyacrylamide gels and in immunoblotting compared with wild-type His 6 -E7 protein (?17 and ?21 kDa, respectively; data not shown), probably because of the introduction of glycine residues that neutralize the overall negative charge, changing the isoelectric properties of the His 6 -E7GGG protein. Subsequently, constructs for mammalian expression were produced. To increase the immunogenicity of the E7 antigen, the E7GGG gene was fused to the sequence encoding the N terminus of the potato virus X (PVX) coat protein (CP). Assembly was performed to the fourth codon of PVX-CP either directly (E7GGG-CP) or via the four-amino acid linker Gly-Pro-Gly-Pro (E7GGG-L-CP). A Kozak sequence to enhance translation was added upstream of the E7GGG, CP, and fusion genes. Cloning was performed into pcDNA3.1(ϩ) mammalian expression vector, downstream of its immediateearly cytomegalovirus promoter (Fig. 1A) .
To verify that pcDNA/E7GGG, pcDNA/E7GGG-CP, and pcDNA/E7GGG-L-CP constructs were able to express the encoded proteins, HEK-293 cells were transiently transfected with the recombinant plasmid DNA. On transfection, mRNA expression of the fusion genes was revealed by RT-PCR showing the presence of bands of the expected molecular mass for all constructs, namely 284 bp for E7GGG (Fig. 1B, lane 1) , 890 bp for E7GGG-CP (Fig. 1B, lane 4) , and 902 bp and E7GGG-L-CP (Fig. 1B, lane 6) .
Western blot analysis was performed on lysates (10 6 cells) 48 hr posttransfection and showed a weak signal corresponding to the E7GGG protein (17 kDa; Fig. 1C, lane 1b) , whereas almost no signal corresponding to the fusion proteins could be detected. On the other hand, immunoprecipitation carried out on 5-fold the number of cells (5 ϫ 10 6 cells) showed that E7GGG-CP and E7GGG-L-CP fusion proteins were produced by transfected cells (40 kDa; Fig. 1C, lanes 2b and 3b) , suggesting that the negative results in immunoblotting may be due to low levels of production or to increased degradation. Therefore, transfected cells were treated with proteasome inhibitors to verify the second hypothesis. Addition of either 10 M lactacystin (data not shown) or 25 M MG-132 caused a dramatic increase in E7GGG, E7GGG-CP, and E7GGG-L-CP proteins content in cellular lysates, with strong band signals corresponding to products of the expected size (Fig. 1C, lanes 1c,  2c, and 3c , respectively). Results obtained with proteasome inhibitors suggest that the fusion of CP to E7GGG destabilizes the protein and leads to enhanced processing through the proteasome-ubiquitin pathway. Immunofluorescence of transfected cells (performed in the absence of proteasome inhibitors) confirmed expression of E7GGG, E7GGG-CP, and E7GGG-L-CP proteins. The E7GGG protein was distributed predominantly in the nucleus and, to a lesser extent, in the cytoplasm (Fig. 1D, panel 1) , whereas fusions proteins showed a cytoplasmic localization with both diffuse and a granular staining, the latter probably corresponding to E7GGG-CP or E7GGG-L-CP protein aggregates (Fig. 1D, panels 2 and 3, respectively) .
E7-CP fusion DNA vaccine inhibits the growth of E7-expressing TC-1 tumors in vivo
In preliminary sets of experiments, fusion of E7GGG with the green fluorescent protein gene did not alter the immunogenicity of the viral protein and the addition of DNA plasmid
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carrying CP alone to several preparations of E7 alone or fused to another peptide, that is, Ubi-E7 or Ii-E7 (De Marco et al., 2003) , did not show any adjuvant activity (data not shown). Afterward, we investigated whether vaccination with pcDNA/ E7GGG, pcDNA/CP, pcDNA/E7GGG-CP, and pcDNA/ E7GGG-L-CP plasmids was able to induce an immune response controlling the growth of E7-expressing TC-1 tumors in vivo. Female C57BL/6 mice (six per group) were challenged subcutaneously with oncogenic TC-1 tumor cells and then inoculated intramuscularly twice with the above-mentioned plasmids in an experimental challenge-immunization setting. Three sets of experiments were performed.
Three weeks after tumor challenge, vaccination with saline solution, pcDNA/CP, or pcDNA/E7GGG resulted in tumor development in 100, 40, and 40% of the animals, respectively (Fig. 2) . On the other hand, vaccination with pcDNA/E7GGG-L-CP plasmid protected 80% of mice, and all the animals vaccinated with the pcDNA/E7GGG-CP fusion construct were tumor free (Fig. 2) .
Thirty days after challenge, tumor growth inhibition elicited by pcDNA/E7GGG-CP vaccine was about 2-fold higher (60%) compared with pcDNA/E7GGG and pcDNA/E7GGG-L-CP, which both showed similar efficacy (about 30%) (Fig. 2) , and it remained constant until control animals were killed for ethi-
FIG. 1. Expression of E7 fusion genes in mammalian cells. HPV-16 E7GGG-based fusion constructs pcDNA/E7GGG, pcDNA/E7GGG-CP, and pcDNA/E7GGG-L-CP were used for transient expression in HEK-293 cells as described in Materials and Methods. (A) Schematic representation of the fusion constructs. Genes were inserted by directional cloning of HindIII and
NotI fragments between the immediate-early cytomegalovirus promoter (P CMV ) and the bovine growth hormone polyadenylation signal (BGHpA) of the pcDNA3.1(ϩ) plasmid (MCS, multiple cloning site; Neo R, neomycin resistance for selection of stably transfected cells). (B) mRNA expression of the fusion genes. Total cellular RNA was extracted from transfected cell preparations. cDNAs were synthesized by RT-PCR and specific amplified products were obtained with different sets of primers as described in Materials and Methods. By using these devised primers, long (comprising E7 and CP sequences) or short (comprising E7 and partial CP sequences) fragments were detected in ethidium bromide-agarose gels. Lane 1, pcDNA/E7GGG; lane 2, PCR positive control using pQE30-E7GGG vector DNA; lane 3, PCR negative control; lanes 4 and 5, pcDNA/E7GGG-CP long and short fragments, respectively; lanes 6 and 7, pcDNA/E7GGG-L-CP long and short fragments, respectively; lanes 8-11, RT-PCR negative controls performed on nontransfected HEK-293 with all the primer sets; lane 12, molecular weight markers, with base pairs (bp) indicated. cal reasons on day 54. Percentage of tumor-free pcDNA/ E7GGG-CP-vaccinated with respect to pcDNA/E7GGG-vaccinated mice was statistically significant according to the logrank test (p ϭ 0.0106). Vaccination with pcDNA/CP protected only 5.5% of the animals (1 of 18 mice).
E7GGG-CP gene induces E7-specific antibody induction
The humoral immune response was evaluated by ELISA. Blood samples were obtained 1 week after the last booster from non-TC-1-challenged animals. Plates were coated with either His 6 -E7 or His 6 -E7GGG purified proteins, and similar results were obtained. However, the relevant biological data should be related only to responses raised against His 6 -E7, the wild-type form of E7 presented to the immune system in natural infections and in established cervical cancer. Although there was variability among the different mice, it was clear that the anti-E7 antibody response developed and reached the highest level after vaccination with pcDNA/E7GGG-CP. This finding has been reproduced in three different experiments. Animals immunized with either pcDNA/E7GGG or pcDNA/E7GGG-L-CP constructs developed a much lower anti-E7 immune response (Fig. 3A) . No E7-specific antibody induction was detected in mice vaccinated with pcDNA/CP plasmid.
E7GGG-CP DNA immunization mediates E7-specific cellular immune response in vivo
The cell-mediated immune response is one of the most crucial components produced by antitumor effectors. To determine the E7-specific CD8 ϩ T cell precursor frequencies generated by immunization with DNA fusion plasmids, ELISPOT was used as a sensitive functional assay to measure IFN-␥ production at the single-cell level. The fusion vaccines were particularly efficient in promoting the cell-mediated immune response, without any significant difference between E7-specific, IFN-␥-secreting CD8 ϩ T cell and CD4 ϩ T cell activity. In fact, in a representative experiment of the three performed, IFN-␥ spotforming CD8 ϩ T cells specific for the immunodominant H-2D brestricted E7 peptide (amino acids 49-57) were detected per 1 ϫ 10 6 splenocytes derived from non-TC-1-challenged mice vaccinated with the various DNA plasmids (Fig. 3B) . With the subtraction of the background related to pcDNA/CP plasmid vaccination (7 spots), mice vaccinated with pcDNA/E7GGG-CP and pcDNA/E7GGG-L-CP plasmids showed 170 and 100 E7-specific CD8 ϩ T cell precursors, respectively.
Splenocytes derived from mice vaccinated with the pcDNA/E7GGG-CP plasmid, stimulated with an E7 peptide containing an MHC class II epitope (amino acids 30-67), generated the highest number (180 spots) of IFN-␥-producing CD4 ϩ T cell precursors, whereas mice vaccinated with pcDNA/E7GGG plasmid showed a signal only slightly above either the pcDNA/CP vector-vaccinated mice or the controls. Immunization with pcDNA/E7GGG-L-CP led to an intermediate value (114 spots). Moreover, non-CD4 ϩ T cell depletion of splenocyte preparations confirmed the increased specific activity of CD4 ϩ T cells mainly in E7GGG-CP-vaccinated animals (data not shown).
DISCUSSION
HR-HPV infections are generally transient and believed to be controlled by the cell-mediated immune response because the majority of HPV-induced lesions spontaneously regress (Eiben et al., 2002) . Nevertheless, a major feature of HPV that
FIG. 2.
Mouse protection against TC-1-induced tumor after therapeutic vaccination with pcDNA/E7GGG, pcDNA/CP, pcDNA/E7GGG-CP, and pcDNA/E7GGG-L-CP plasmids. Data are presented as the percentage of tumor-free mice. C57BL/6 mice were challenged subcutaneously on day 0 with 5 ϫ 10 4 E7-expressing TC-1 tumor cells. One hundred microliters of plasmid DNA was administered intramuscularly on days 3 and 10 with either the indicated vaccine preparations or saline solution as control. The presence of tumors in mice was monitored by palpation twice per week. The animals were killed on day 54 after tumor challenge, when all the animals with tumors were killed for ethical reasons. Results derive from cumulative data of three performed experiments (total, 18 animals per group), which were analyzed by log-rank test. A difference between groups was considered significant if p Ͻ 0.05. In particular, ˆp Ͻ 0.0001 (pcDNA/E7GGG or pcDNA/E7GGG-L-CP vs. control); °p ϭ 0.0106 (pcDNA/E7GGG-CP vs. pcDNA/E7GGG-L-CP or pcDNA/E7GGG); § p Ͻ 0.0001 (pcDNA/E7GGG-CP vs. control). might impair HPV therapeutic vaccination is the poor presentation of viral antigens, which are expressed at a low level, and the poor trafficking of effector T cell populations to noninflamed mucosal/skin sites (Tindle, 2002) . Moreover, therapeutic vaccination against established cervical cancer is particularly challenging as it should overcome tolerance and activate the cellular components of the compromised immune system of the patient.
DNA vaccination is an attractive approach for HPV immunotherapy and clinical trials with E7-based DNA vaccines are in progress (Frazer, 2004) . The E7 oncoprotein of human papillomavirus type 16 (HPV-16) is a tumor antigen and, as for the majority of candidate tumor antigens, is intracellular and present only in peptide units in the groove of the MHC class I molecule. Only CD8 ϩ T cells, assisted by CD4 ϩ specific helper T cells, can recognize these peptides and, after this event, develop into effector CTLs capable of killing the target cells.
Several strategies have been adopted to activate cell-mediated immunity against the weak E7 tumor antigen in DNA vaccines, such as fusion with sequences able to enhance intracellular targeting or intercellular spreading (Moniz et al., 2003) . However, some concerns have been raised about the possibil- immune responses after vaccination with saline solution, pcDNA/E7GGG, pcDNA/ E7GGG-CP, pcDNA/E7GGG-L-CP, and pcDNA/CP plasmids are reported from a representative experiment of three performed. C57BL/6 mice were immunized twice, with a 1-week interval, by intramuscular administration of the various plasmids as described in Materials and Methods. Humoral E7-specific serum IgG responses are presented as optical density values at 405 nm of 1:100 diluted sera. The mean titer value from each group of sera is marked with a dash. pcDNA/E7GGG-CP triggered a better specific anti-E7 antibody response than did pcDNA/E7GGG-L-CP, with means and variance values between pcDNA/ E7GGG-CP and pcDNA/E7GGG-L-CP-immunized mice significantly different according to Student t test (p means ϭ 0.0071 and p variances ϭ 0.0198). The cellular immune response was detected by ELISPOT assay for IFN-␥-secreting splenocytes as described in Materials and Methods. Data are presented as mean spot number Ϯ SD per 1 ϫ 10 6 splenocytes from triplicate wells. Shaded and solid columns refer to cells stimulated either with MHC class I (amino acids 49-57) or MHC class II (amino acids 30-67) E7 peptides, respectively. Open columns represents nonstimulated splenocytes.
ity that vaccination with DNA encoding human or highly conserved sequences might cause autoimmune reactions. As an example, anti-calreticulin antibodies have been identified in patients with the autoimmune disease systemic lupus erythematosus and in patients with other autoimmune diseases (Eggleton and Llewellyn, 1999; Peng et al., 2006) . In addition, although the peptide chaperone function of HSP70 is a welldocumented mechanism for enhancing MHC class I-restricted immune responses to associated peptides, some data suggest that HSPs can promote autoimmunity in vivo (Millar et al., 2003) . Thus, most fusions do not completely fulfill the requirements for a safe genetic vaccine and at present no general criterion is available for the rational design of an effective genetic fusion vaccine.
Genes encoding microbial proteins fused to tumor antigen sequences have already been exploited in DNA vaccination (Pardoll, 1998) . As an example, the fusion with bacterial ␤-glucuronidase (GUS) was shown to improve E7 immunogenicity (Smahel et al., 2004) . A relatively new class of pathogen-derived sequences is represented by plant viral coat proteins (CPs). They can be used as carriers for several reasons: plant viruses are not human pathogens; they are able to self-assemble or to form highly immunogenic aggregates; and no evidence of preexisting immunity in humans has been described (Savelyeva et al., 2003) .
Therefore, in a search for new formulations able to improve the safety and immunogenicity of therapeutic vaccines, as a prelude to translation in clinical practice, we used the potato virus X coat protein gene (PVX-CP). We have already used PVX as a vector for the transient expression of E7 protein in plants (Franconi et al., 2002) and other studies have demonstrated the advantages of PVX as an epitope presentation system in protein vaccination. In particular, it has been reported that linkage of B cell epitopes to PVX-CP induced a potent IgG2a isotype response in mice (Marusic et al., 2001) , indicating that the nature of the carrier molecule is able to direct the immune system toward a helper T cell type 1 (Th1) response. Moreover, it has been described that the fusion of a tumor antigen to the N terminus of PVX-CP, endowed with a signal sequence for secretion, when administered in DNA form, leads to self-assembling structures able to increase CD4 ϩ T cell-mediated protection (Savelyeva et al., 2001) . This can be ascribed to the "linked T cell help" phenomenon, in which an immunologically silent or poor determinant becomes immunogenic if linked to a dominant pathogen-derived antigen (Gerloni et al., 2000) . Therefore, we hypothesized that a DNA fusion vaccine that includes PVX-CP would likely direct the response against an attached antigen toward the Th1 type, which is decisive in cancer immunotherapy.
In the present work the PVX-CP was chosen as an alternative "promotion" gene to be fused with an attenuated HPV-16 E7 gene, devoid of oncogenic potential in human cells. In fact, E7 interacts with retinoblastoma protein (pRb), inducing its functional inactivation, a crucial step for cervical carcinogenesis. The oncogenic properties of HPV-16 E7 have been impaired in several ways (Doan et al., 2000; Munger et al., 2001; Smahel et al., 2001; Ohlschlager et al., 2006) . We introduced three point mutations into the pRb-binding site of the E7 oncogene to abolish transformation potential (the E7GGG gene) (Smahel et al., 2001) . Because the E7 oncoprotein contains identified MHC class I CTL and helper T cell epitopes, the use of the entire coding region has the advantage that no HLA restrictions apply for widespread vaccine formulations.
E7 is known to be an unstable protein (Reinstein et al., 2000) and the introduced mutations did not further affect its stability. Indeed, it was straightforward to produce His 6 -E7GGG as a soluble protein from E. coli and to purify it under native conditions.
The reciprocal orientation of E7GGG and CP within the fusion was dictated by several considerations. First, PVX-CP has the N terminus exposed on the viral surface (Parker et al., 2002) and fusion of exogenous sequences at the 5Ј terminus of the gene, which does not disrupt the ability of PVX-CP to self-assemble, is tolerated (Cruz et al., 1996) . Furthermore, because E7 is degraded in vivo through the ubiquitin-proteasome pathway by N-terminal ubiquitination (Reinstein et al., 2000) , the position of E7 within the fusion at the N terminus should preserve the E7 MHC class I processing pathway.
The fusion genes were cloned into a mammalian expression plasmid and used to transfect mammalian cells. Because mRNA analysis demonstrated expression of all constructs, whereas the E7GGG-CP or E7GGG-L-CP protein products could be clearly detected only after immunoprecipitation, we hypothesized that fusion proteins underwent more rapid degradation compared with the unfused E7GGG gene. Our data concerning transfection experiments in the presence of proteasome inhibitors confirm that in HEK-293 cells the CP-derived E7 fusion proteins are even more efficiently degraded by the ubiquitin-proteasome pathway than E7GGG alone. In addition, the cytoplasmic granular bodies observed by immunofluorescence may represent either E7GGG-CP or E7GGG-L-CP protein aggregates prone to degradation; these are probably different from the extracellular particles previously observed by electron microscopy (Savelyeva et al., 2001) , which likely correspond to secreted, selfassembled PXV-CP-derived fusion proteins.
The curative potential of our vaccines was determined in a preclinical papillomavirus model. Plasmids carrying the fusion genes were used to inoculate mice in an experimental therapeutic vaccination protocol. The route of administration is known to play an important role in induction of immunity (Pardoll, 1998) . The observed intracellular processing and degradation pathway of our constructs suggested that intradermal immunization via gene gun (whereby the encoded protein mainly enters the MHC class I processing pathway through direct transfection of APCs) could improve vaccine efficacy. Indeed, we started experiments with the same plasmids to address this issue (Massa et al., unpublished data) . Intramuscular immunization, on the other hand, likely targets antigen to myocytes and the DNA-encoded antigen is finally presented through bone marrow-derived APCs through cross-priming, which possibly involves release of the antigen to be taken up and processed by other APCs via the MHC class I-restricted pathway. However, because the cross-priming process is incompletely understood, the uncertainty about this point makes a rational vaccine design more difficult. We decided to use the intramuscular route as an empirical approach to the vaccination schedule in an attempt to diversify the immune response, keeping in mind that this route of administration is more suitable for clinical application.
Addition of the DNA plasmid carrying CP alone to several preparations of E7 alone or fused to other peptides did not show any increased immunogenicity, indicating that adjuvant activity was linked to the fusion of CP with E7GGG in the same construct. Our vaccination data with fusion vaccines demonstrate that the E7GGG-CP construct, administered intramuscularly to C57BL/6 mice, is able to significantly inhibit tumor growth. In fact, maximal efficacy was demonstrated with the E7GGG-CP construct (60% tumor-free animals) with respect to E7GGG-L-CP and unfused E7GGG constructs (about 30%). Slight activity was also demonstrated by the pcDNA/CP plasmid (5.5%).
The activity of a DNA vaccine vector scaffold has already been reported and seems to be linked to the stimulation of innate immunity by the activation of Toll-like receptor via CpG motifs within the plasmid sequence (Stewart et al., 2003) . Hence, because DNA vaccination can exert nonspecific protection, we performed a parallel experiment in which mice were challenged with a non-E7-expressing tumor cell line, C-108, derived from mouse lung tumor (De Marco et al., 2003) , in which no animal was protected after vaccination with our constructs (data not shown), indicating that the effects of vaccines are antigen specific. Finally, some nonspecific protection might also be due to the CP sequence, which indeed seems to be unable to trigger any E7-specific adaptive immune response, as indicated by ELISPOT and serum IgG analyses. On the contrary, E7GGG-CP inhibited tumor growth and induced humoral as well as cell-mediated immune responses. The antibody immune response elicited by fusion vaccines could be explained, at least in part, by the non-self nature of the carrier protein. An optimal response to a therapeutic vaccine has been shown to be dependent on the activation of CD4 ϩ helper T cells (Hung et al., 1998; Brulet et al., 2007) . The fusion constructs were able to induce activation of both CD4 ϩ and CD8 ϩ cells, as indicated by the production of IFN-␥ by splenocytes in response to CD4-and CD8-specific epitopes. The highest efficacy in producing a CD4 ϩ /CD8 ϩ response was elicited by E7GGG-CP. The activity of this construct was also compared with that of the Ii-E7 construct (De Marco et al., 2003; Brulet et al., 2007) demonstrating, in an in vivo assay (Brulet et al., 2007) , specific CTL activity associated with CD4 ϩ cell stimulation (A. Venuti, unpublished data) . This might be explained as an effect of increased degradation of the E7GGG-CP fusion observed in transfection experiments. However, the introduction of small changes, such as the interposition of a linker in E7GGG-L-CP, abolished the enhancing effect of antitumor activity, even though intracellular degradation was not altered.
The observed enhancement in antitumor activity could be due to CD4 ϩ helper T cells generated by the CP portion of the fusion construct. Unfortunately, no data are available on MHC class I-or MHC class II-restricted PVX-CP epitopes for C57BL/6 mice and, therefore, this hypothesis remains to be addressed. Nevertheless, the induction of CD4 ϩ T cells specific for immunoenhancing sequences was reported to be involved in priming CD8 ϩ responses against tumor antigens (Stevenson et al., 2004) .
It has been suggested that an increased number of DNA vaccine doses might induce higher E7-specific CTL activity and a stronger antitumor response (Cheng et al., 2002) . However, when we performed a different immunization protocol with multiple doses (four 100-g doses at 1-week intervals) after challenge, we did not observe any significant difference, either in the quality of the T cell response or in the frequency of tumor-free mice (data not shown).
Fusion of a short E7-derived sequence (amino acids 44-60) to the 3Ј end of the gene encoding the CP of another plant virus (potato virus A, PVA) has been reported (Pokorna et al., 2005) . Therapeutic DNA vaccination experiments performed with this construct resulted in enhanced tumor protection with respect to the E7 gene alone, but lower if compared with our constructs (37.5 vs. 60%, respectively), probably because only an E7-derived peptide was used or because of the relative position of the E7 gene in the fusion construct.
In conclusion, vaccination with a modified E7 gene C-terminally fused to PVX-CP was able to significantly increase the cellular immune response, reduce tumor growth, and enhance survival of mice in therapeutic experiments, compared with mice vaccinated with the E7GGG gene alone, probably because of some feature of this plant pathogen-derived antigen, that is, the absence of preexisting immunity and the ability to self-assemble or to form highly immunogenic aggregates.
Taken together, these results indicate that this design may represent an innovative way to simultaneously reduce the transformation potential of the HPV-16 E7 gene, enhance immunogenicity of the encoded product, and reduce concerns about inappropriate immune responses or autoimmunity in therapeutic vaccination regimens to treat cervical cancer.
